Mecapegfilgrastim to help collect stem cells for transplant
Treatments studied
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This Phase 2 study tests mecapegfilgrastim with chemotherapy to help your body collect enough peripheral blood stem cells for an autologous transplant (using your own cells). It’s for people with multiple myeloma or certain lymphomas who have already had some response to treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have multiple myeloma (one prior treatment line) or lymphoma (two or fewer prior treatment lines)
- Your disease has at least partially responded to past treatment
- You are eligible to get an autologous stem cell transplant using your own stem cells
- You are age 18–65, and your daily function is good (ECOG 0–1)
- You have enough time to live with benefit (more than 3 months) and can sign written consent
- If you can become pregnant, you must use reliable birth control during the study and for 90 days after the last dose, with a negative pregnancy test before starting
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests two different combinations of medicines to help collect stem cells for a transplant in people newly diagnosed with multiple myeloma. The goal is to see which approach works better and is safer for you.
This Phase 1 study tests a carfilzomib-based treatment plan to help people with multiple myeloma collect enough stem cells for an autologous (using your own) stem cell transplant. It’s mainly about whether this mobilization approach works and is safe for you.
This trial tests a new drug, motixafortide, combined with a standard growth factor (G-CSF) to help collect stem cells for a transplant in people with multiple myeloma. It may be a good option if your myeloma is in remission and you have not had a stem cell transplant before.
This trial tests a specific chemotherapy combination (thiotepa and melphalan) given before a stem cell transplant to treat multiple myeloma. The study compares this approach to help doctors understand if it improves outcomes for patients whose myeloma hasn't fully responded to initial treatment.
This Phase 2 study tests eltrombopag to improve collection of peripheral blood stem cells in adults with Hodgkin or non-Hodgkin lymphoma. If you’re getting a planned chemotherapy mobilization (like ESHAP, with or without an antibody), this trial may see whether eltrombopag can help your body collect the needed stem cells for transplant or further treatment.
This study tests if adding Mozobil (a drug that helps release stem cells) before stem cell transplant can improve outcomes for people with multiple myeloma, Hodgkin's lymphoma, or non-Hodgkin lymphoma. If you are eligible, you will receive Mozobil along with standard stem cell mobilization medicines.
Hear when a new Multiple myeloma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.